Related Experiment Videos
[Activity of ondansetron on the systemic vascular resistance and venous capacitance during cardiopulmonary bypass]
J Sánchez-Peña1, J Luis-Navarro, C Pérez-Torres
1Servicio de Anestesiología y Reanimación, Hospital Universitario Virgen del Rocío, Sevilla.
Objective:
To study the effect of ondansetron administered during cardio-pulmonary bypass surgery, in terms of mean arterial pressure, systemic vascular resistance and venous system capacitance.
Patients And Method:
Twenty patients scheduled for non coronary cardiac surgery were randomly assigned to 2 groups. The study group received 4 mg ondansetron during the bypass and the control group received the same volume of physiological saline solution. The following parameters were recorded during the 10 minutes following administration of either substance: mean arterial pressure, calculated systemic vascular resistance, and the venous reservoir volume at the beginning and end of the study period.
Results:
Increased mean arterial pressure and systemic vascular resistance were recorded in both groups from the time of injection, with the highest levels recorded at 10 minutes. There were no statistical differences between the 2 groups. No changes in venous system capacitance were observed in either group, as there were no significant changes in venous reservoir volume of the extracorporeal circulation pump.
Conclusions:
Ondansetron at the dose used has no effect on arterial or venous vessels. The increased resistance recorded in both groups can be attributed to the release of catecholamines during non pulsatile extracorporeal circulation with a non pulsatile flow.
Insights
Ondansetron did not affect blood pressure or vascular resistance during cardiac surgery. This study found no changes in venous capacitance, suggesting the drug is safe for use in cardiopulmonary bypass procedures.
Area of Science:
- Cardiovascular Anesthesiology
- Pharmacology
- Surgical Research
Background:
- Cardiopulmonary bypass (CPB) surgery requires careful hemodynamic management.
- Ondansetron is a 5-HT3 antagonist used to prevent nausea and vomiting.
- The hemodynamic effects of ondansetron during CPB are not well-established.
Purpose of the Study:
- To investigate the impact of ondansetron on hemodynamic parameters during CPB.
- Specifically, to assess its effects on mean arterial pressure (MAP), systemic vascular resistance (SVR), and venous system capacitance.
Main Methods:
- A randomized controlled trial involving 20 patients undergoing non-coronary cardiac surgery.
- Patients received either 4 mg of ondansetron or a saline placebo during CPB.
- Hemodynamic parameters including MAP, SVR, and venous reservoir volume were monitored for 10 minutes post-administration.
Main Results:
- Both ondansetron and placebo groups showed increased MAP and SVR post-administration, peaking at 10 minutes.
- No statistically significant differences in MAP or SVR were observed between the ondansetron and placebo groups.
- No changes in venous system capacitance were detected in either group.
Conclusions:
- Ondansetron, at the tested dosage, does not exert significant effects on arterial or venous vasculature during CPB.
- The observed increases in vascular resistance in both groups are likely due to the non-pulsatile flow of extracorporeal circulation and associated catecholamine release.
- Ondansetron appears hemodynamically neutral in the context of CPB.